The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis

被引：0
|
作者：
Deodhar, Atul
Mease, Philip
Machado, Paula
Pournara, Effie
Meng, Xiangyi
Strand, Vibeke
Magrey, Marina
机构：
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
EFFICACY; SAFETY;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0350
引用
收藏
页数：4
相关论文
共 50 条
  • [31] SECUKINUMAB SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM MEASURE 2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING
    Sieper, J.
    Braun, J.
    Baraliakos, X.
    Baeten, D. L.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Wei, J. C. -C.
    Porter, B.
    Andersson, M.
    Mpofu, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 132 - 133
  • [32] SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE OVER LONG-TERM EXPOSURE (UP TO 4 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS - UPDATED POOLED ANALYSIS OF THREE PHASE 3 TRIALS
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Martin, R.
    Porter, B.
    Shete, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 727 - 727
  • [33] NO INCREASED INCIDENCE OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Schreiber, S.
    Sands, B. E.
    Deodhar, A.
    Baeten, D.
    Huang, J.
    Gandhi, K.
    Karyekar, C.
    Fox, T.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 97 - 98
  • [34] NO INCREASED RISK OF INFLAMMATORY BOWEL DISEASE AMONG SECUKINUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PSORIASIS, PSORIATIC ARTHRITIS, OR ANKYLOSING SPONDYLITIS: DATA FROM 14 PHASE 2 AND PHASE 3 CLINICAL STUDIES
    Zochling, J.
    Deodhar, A.
    Schreiber, S.
    Gandhi, K.
    Fox, T.
    Gaillez, C.
    Karyekar, C.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 39
  • [35] No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
    Deodhar, Atul A.
    Schreiber, Stefan
    Gandhi, Kunal
    Fox, Todd
    Gaillez, Corine
    Karyekar, Chetan
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
    Kishimoto, Mitsumasa
    Taniguchi, Atsuo
    Fujishige, Ayako
    Kaneko, Shuhei
    Haemmerle, Sibylle
    Porter, Brian O.
    Kobayashi, Shigeto
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 132 - 140
  • [37] SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR DATA FROM MEASURE 1, A PHASE 3 RANDOMISED TRIAL
    Emery, P.
    Baeten, D.
    Deodhar, A.
    Wei, A.
    Geusens, P.
    Talloczy, Z.
    Gong, Y.
    Porter, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 818 - 818
  • [38] Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
    Braun, Juergen
    Buehring, Bjoern
    Baraliakos, Xenofon
    Gensler, Lianne S.
    Porter, Brian
    Quebe-Fehling, Erhard
    Haemmerle, Sibylle
    BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)
  • [39] Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
    Jürgen Braun
    Bjoern Buehring
    Xenofon Baraliakos
    Lianne S. Gensler
    Brian Porter
    Erhard Quebe-Fehling
    Sibylle Haemmerle
    BMC Musculoskeletal Disorders, 22
  • [40] Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
    Braun, Juergen
    Buehring, Bjoern
    Baraliakos, Xenofon
    Gensler, Lianne S.
    Porter, Brian
    Shete, Abhijit
    Quebe-Fehling, Erhard
    Haemmerle, Sibylle
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345